These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 24345529

  • 21. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy.
    Pollack A, Staurenghi G, Sager D, Mukesh B, Reiser H, Singh RP.
    Br J Ophthalmol; 2017 Apr; 101(4):423-427. PubMed ID: 27388251
    [Abstract] [Full Text] [Related]

  • 22. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group.
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [Abstract] [Full Text] [Related]

  • 23. Effect of nepafenac eye drops on pain associated with pterygium surgery.
    Ozcimen M, Sakarya Y, Goktas S, Sakarya R, Yener HI, Bukus A, Demir LS.
    Eye Contact Lens; 2015 May; 41(3):187-9. PubMed ID: 25603438
    [Abstract] [Full Text] [Related]

  • 24. Nepafenac: new drug. After cataract surgery: just another NSAID eye drop. No better than other NSAID eye drops, and less convenient to use.
    Prescrire Int; 2009 Aug; 18(102):156. PubMed ID: 19743570
    [No Abstract] [Full Text] [Related]

  • 25. 0.1% Nepafenac reduces pain and increases patient comfort during cataract surgery.
    Oğurel T, Oğurel R, Onaran Z, Örnek K.
    Cont Lens Anterior Eye; 2018 Oct; 41(5):448-451. PubMed ID: 29807771
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK, Roel L, Siou-Mermet R, Erb T.
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [Abstract] [Full Text] [Related]

  • 27. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studies.
    Hovanesian JA, Sheppard JD, Trattler WB, Gayton JL, Malhotra RP, Schaaf DT, Ng E, Dunn SH.
    J Cataract Refract Surg; 2015 Oct; 41(10):2060-8. PubMed ID: 26703280
    [Abstract] [Full Text] [Related]

  • 28. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
    Tzelikis PF, Vieira M, Hida WT, Motta AF, Nakano CT, Nakano EM, Alves MR.
    Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
    [Abstract] [Full Text] [Related]

  • 29. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery.
    Naithani P, Puranik S, Vashisht N, Khanduja S, Kumar S, Garg S.
    Retina; 2012 Feb; 32(2):250-5. PubMed ID: 21926942
    [Abstract] [Full Text] [Related]

  • 30. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [Abstract] [Full Text] [Related]

  • 31. Nepafenac Ophthalmic Suspension 0.3% for the Management of Ocular Pain After Photorefractive Keratectomy.
    Kontadakis GA, Chronopoulou KG, Tsopouridou R, Tabibian D, Kymionis GD.
    J Refract Surg; 2018 Mar 01; 34(3):171-176. PubMed ID: 29522226
    [Abstract] [Full Text] [Related]

  • 32. Effect of Topical Nonsteroidal Anti-inflammatory Drugs on Pupillary Size During Uncomplicated Cataract Surgery.
    Rodríguez-García A, Hernández-Camarena JC, López-Jaime GR, Nava-García JA.
    J Refract Surg; 2017 Apr 01; 33(4):236-242. PubMed ID: 28407163
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the Effect of Diclofenac 0.1% and Nepafenac 0.1% on Aqueous Flare in Patients Undergoing Cataract Surgery: A Prospective Randomized Study.
    Cagini C, Pellegrino A, Cerquaglia A, Iaccheri B, Lupidi M, Fiore T.
    Curr Eye Res; 2020 Sep 01; 45(9):1089-1093. PubMed ID: 32004437
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery.
    Weber M, Kodjikian L, Kruse FE, Zagorski Z, Allaire CM.
    Acta Ophthalmol; 2013 Feb 01; 91(1):e15-21. PubMed ID: 22970738
    [Abstract] [Full Text] [Related]

  • 35. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
    Lindstrom R, Kim T.
    Curr Med Res Opin; 2006 Feb 01; 22(2):397-404. PubMed ID: 16466612
    [Abstract] [Full Text] [Related]

  • 36. Comparison of once daily dose of 0.3% nepafenac alone and three times dose of 0.1% nepafenac alone in pain and inflammation control after phacoemulsification.
    Bardoloi N, Sarkar S, Burgute PS, Deb AK, Dholkawala R, Aggarwal P, Gokhale T.
    Indian J Ophthalmol; 2022 Mar 01; 70(3):807-812. PubMed ID: 35225519
    [Abstract] [Full Text] [Related]

  • 37. Safety and Efficacy of 0.1% Nepafenac versus 1% Prednisolone Acetate Eye Drops after Laser Peripheral Iridotomy: A Prospective, Randomized Trial.
    Gayam K, Ramulu PY, Rengaraj V, Srinivasan K.
    Ophthalmol Glaucoma; 2020 Mar 01; 3(3):174-180. PubMed ID: 32672612
    [Abstract] [Full Text] [Related]

  • 38. Effect of nepafenac eye drops on intraocular pressure: a randomized prospective study.
    Dave P, Shah K, Ramchandani B, Jain R.
    Am J Ophthalmol; 2014 Mar 01; 157(3):735-8.e1-2. PubMed ID: 24345317
    [Abstract] [Full Text] [Related]

  • 39. Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5.
    Hovanesian J, Holland E.
    J Cataract Refract Surg; 2019 Feb 01; 45(2):174-180. PubMed ID: 30527440
    [Abstract] [Full Text] [Related]

  • 40. Pain Control after Intravitreal Injection Using Topical Nepafenac 0.3% or Pressure Patching: A Randomized, Placebo-Controlled Trial.
    Kaplan RI, Drinkwater OJ, Lee RH, Chod RB, Barash A, Giovinazzo JV, Gologorsky D, Jansen ME, Rosen RB, Gentile RC.
    Ophthalmol Retina; 2019 Oct 01; 3(10):860-866. PubMed ID: 31221565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.